Company Description
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia.
It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.
The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection.
It is also developing other dry powder products, such as Augmenta monoclonal antibodies for the treatment of COVID-19 therapeutics; TFF Niclosamide, which is completed Phase 1 clinical trials for the treatment of COVID-19 disease; and other vaccines.
TFF Pharmaceuticals, Inc. has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop Augmenta monoclonal antibodies; a licensing and collaboration agreement with UNION therapeutics A/S; and a collaborative research and development agreement with the National Institute of Environmental Health Sciences to develop dry powder formulations of hyaluronan to prevent and treat respiratory diseases.
The company was incorporated in 2018 and is headquartered in Fort Worth, Texas.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 25, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Dr. Harlan F. Weisman |
Contact Details
Address: 2600 Via Fortuna, Suite 360 Austin, Texas 78746 United States | |
| Phone | 737-802-1973 |
| Website | tffpharma.com |
Stock Details
| Ticker Symbol | TFFP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001733413 |
| CUSIP Number | 87241J104 |
| ISIN Number | US87241J2033 |
| Employer ID | 82-4344737 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Harlan F. Weisman | President, Chief Executive Officer and Director |
| Kirk Allen Coleman | Chief Financial Officer, Treasurer and Secretary |
| Dr. Zamaneh Mikhak M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2024 | ARS | Filing |
| Apr 22, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 18, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 8, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 2, 2024 | D | Notice of Exempt Offering of Securities |
| Mar 28, 2024 | 8-K | Current Report |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 27, 2024 | 8-K | Current Report |
| Mar 22, 2024 | 8-K | Current Report |